Brii Biosciences Sets 2026 AGM to Approve Accounts, Board Mandates and Share Issuance Authority

Brii Biosciences Limited ( (HK:2137) ) has shared an update.

Brii Biosciences Limited has called its annual general meeting for June 16, 2026, to be held online via the Vistra eVoting Portal, where shareholders will review and adopt the audited financial statements for the year ended December 31, 2025, and receive reports from the board and the external auditor. The agenda also includes re-election of key board members, re-appointment of Deloitte Touche Tohmatsu as auditor, and consideration of a general mandate authorizing directors to issue up to 20% of the company’s share capital, which could provide financial flexibility and support future capital-raising or strategic initiatives.

These governance proposals underscore Brii Biosciences’ efforts to maintain board continuity, strengthen oversight, and preserve access to equity financing tools within Hong Kong listing rules. For shareholders and other stakeholders, the AGM decisions may influence the company’s capital structure, leadership stability, and its ability to respond to market opportunities or funding needs in the coming year.

The most recent analyst rating on (HK:2137) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on Brii Biosciences Limited stock, see the HK:2137 Stock Forecast page.

More about Brii Biosciences Limited

Brii Biosciences Limited is a biopharmaceutical company listed on the Hong Kong Stock Exchange, focused on developing and commercializing innovative therapies. The company operates through its subsidiaries and is governed by a board comprising executive and independent non-executive directors, supported by external auditors for its financial reporting.

Average Trading Volume: 1,258,671

Technical Sentiment Signal: Sell

Current Market Cap: HK$1.06B

For an in-depth examination of 2137 stock, go to TipRanks’ Overview page.